These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Triple-negative breast cancer: current state of the art. Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S Tumori; 2010; 96(6):875-88. PubMed ID: 21388048 [TBL] [Abstract][Full Text] [Related]
3. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427 [TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy of triple-negative breast cancer. Arslan C; Dizdar O; Altundag K Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211 [TBL] [Abstract][Full Text] [Related]
6. Beyond triple-negative breast cancer: the need to define new subtypes. Constantinidou A; Jones RL; Reis-Filho JS Expert Rev Anticancer Ther; 2010 Aug; 10(8):1197-213. PubMed ID: 20735307 [TBL] [Abstract][Full Text] [Related]
7. Triple negative breast cancers: clinical and prognostic implications. Dawson SJ; Provenzano E; Caldas C Eur J Cancer; 2009 Sep; 45 Suppl 1():27-40. PubMed ID: 19775602 [TBL] [Abstract][Full Text] [Related]
8. Molecular stratification of triple-negative breast cancers. Perou CM Oncologist; 2011; 16 Suppl 1():61-70. PubMed ID: 21278442 [TBL] [Abstract][Full Text] [Related]
9. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Diaz LK; Cryns VL; Symmans WF; Sneige N Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131 [TBL] [Abstract][Full Text] [Related]
10. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515 [TBL] [Abstract][Full Text] [Related]
11. Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. Richardson J; Shaaban AM; Kamal M; Alisary R; Walker C; Ellis IO; Speirs V; Green AR; Bell SM Breast Cancer Res Treat; 2011 Jun; 127(3):639-48. PubMed ID: 20632086 [TBL] [Abstract][Full Text] [Related]
12. What is triple-negative breast cancer? Irvin WJ; Carey LA Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097 [TBL] [Abstract][Full Text] [Related]
13. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. Venkitaraman R Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996 [TBL] [Abstract][Full Text] [Related]
14. PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Domagala P; Huzarski T; Lubinski J; Gugala K; Domagala W Breast Cancer Res Treat; 2011 Jun; 127(3):861-9. PubMed ID: 21409392 [TBL] [Abstract][Full Text] [Related]
15. Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Irshad S; Ellis P; Tutt A Curr Opin Oncol; 2011 Nov; 23(6):566-77. PubMed ID: 21986848 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic options for triple-negative breast cancers with defective homologous recombination. Jaspers JE; Rottenberg S; Jonkers J Biochim Biophys Acta; 2009 Dec; 1796(2):266-80. PubMed ID: 19616605 [TBL] [Abstract][Full Text] [Related]
17. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Anders CK; Carey LA Clin Breast Cancer; 2009 Jun; 9 Suppl 2(Suppl 2):S73-81. PubMed ID: 19596646 [TBL] [Abstract][Full Text] [Related]
18. BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype. Santarosa M; Maestro R Cancer Metastasis Rev; 2012 Jun; 31(1-2):131-42. PubMed ID: 22101651 [TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Bosch A; Eroles P; Zaragoza R; Viña JR; Lluch A Cancer Treat Rev; 2010 May; 36(3):206-15. PubMed ID: 20060649 [TBL] [Abstract][Full Text] [Related]
20. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]